NCT01331434已完成不适用
A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fed Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 1
- 主要终点
- bioequivalence determined by statistical comparison Cmax
研究概览
简要总结
The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs.
- •History of allergic or adverse response to exemestane or any comparable or similar product.
结局指标
主要结局
bioequivalence determined by statistical comparison Cmax
时间窗: 21 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsBreast CancerNCT01331421Roxane Laboratories48
已完成
不适用
Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsBreast CancerNCT01331447Roxane Laboratories12
撤回
1 期
Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy SubjectsHealthyNCT01760980Actavis Inc.
已完成
1 期
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast CancerBreast CancerEstrogen Receptor Positive Breast CancerNCT02820961Syndax Pharmaceuticals61
已完成
2 期
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast CancerBreast CancerNCT00767520Bristol-Myers Squibb155